Literature DB >> 16033397

Detection of contact hypersensitivity to corticosteroids in allergic contact dermatitis patients who do not respond to topical corticosteroids.

Müzeyyen Gönül1, Ulker Gül.   

Abstract

The delayed hypersensitivity development against topical corticosteroids which are used in allergic contact dermatitis (ACD) treatment is an important clinical problem. In our study, 41 ACD patients who did not show any response to topical corticosteroid treatment were patch tested with corticosteroid series and the commercial preparations of corticosteroids and their vehicles. In corticosteroid series, there were budesonide, bethametasone-17-valerate, triamcinolone acetonide, tixocortol pivalate, alclomethasone-17-21-dipropionate, clobetasole-17-propionate, dexamethasone-21-phosphate disodium and hydrocortisone-17-butyrate. We detected positive reaction to corticosteroids in 9 of our cases (22%) (5 single and 4 multiple). The sensitivity was mostly produced by tixocortol pivalate (6 patients). This was followed by triamcinolone acetonide (2 patients) budesonide (2 patients), alclomethasone dipropionate (2 patients), dexamethasone 21 phosphate disodium (2 patients) and betamethasone-17-valerate (1 patient). As a result, it should not be forgotten that the corticosteroids used to treat ACD patients may cause ACD themselves. In ACD patients who did not respond to corticosteroid treatment, routinely applying patch test with corticosteroids should be helpful in directing the treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033397     DOI: 10.1111/j.0105-1873.2005.00638.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  1 in total

1.  Contact allergy in the population of patients with chronic inflammatory dermatoses and contact hypersensitivity to corticosteroids.

Authors:  Marek Kot; Jarosław Bogaczewicz; Beata Kręcisz; Anna Woźniacka
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.